Off-Beat Holiday Club and Another v Sanbonani Holiday Spa Shareblock Limited and Others

The first respondent, Sanbonani Holiday Spa Shareblock Limited (Shareblock), was registered as a share block company in 1987. The third respondent, Mr Harri, owned 80% of the second respondent, Sanbonani Development Limited (Development), and 46.7% of Shareblock's shares. The applicants, Off-Beat Holiday Club and Flexi Holiday Club (the Clubs), were minority shareholders owning 29.14% of Shareblock. In 1988, Shareblock amended its articles of association, conferring on Development a continuous right to use common facilities and unlimited discretion to develop a resort as a timeshare holiday establishment with different share allocations. Disputes arose in 1999 regarding a VAT refund being paid to Development instead of Shareblock, and land appropriation. Further disputes arose in 2004. In October 2008, the Clubs launched proceedings in the High Court seeking relief under section 252 of the Companies Act 61 of 1973, claiming that the creation and allocation of shares were invalid and that the articles should be cancelled. They also sought relief under section 266 (derivative action). The respondents argued that both claims had prescribed under the Prescription Act 68 of 1969.

• Whether a claim brought under section 252 of the Companies Act 61 of 1973 constitutes a 'debt' for purposes of the Prescription Act 68 of 1969
• The proper interpretation of the term 'debt' as it appears in sections 10(1) and 11(d) of the Prescription Act, having regard to section 39(2) of the Constitution
• Whether the acts complained of by the applicants constitute continuing wrongs not subject to prescription
• Whether the applicants' section 252 claim had prescribed
• The nature and scope of relief available under section 252 of the Companies Act

Leave to appeal granted. The appeal against the Supreme Court of Appeal's order dismissing the section 252 relief was upheld. The order of the SCA relating to section 252 claims was set aside and replaced with: (1) a declaration that a claim brought under section 252 of the Companies Act 61 of 1973 does not constitute a debt in terms of the Prescription Act 68 of 1969; (2) the matter was postponed sine die to enable the applicants to enrol the matter for adjudication of the merits of the section 252 claims; (3) costs were reserved. The respondents were ordered to pay the applicants' costs in the Constitutional Court and Supreme Court of Appeal, including costs of two counsel.

A claim brought under section 252 of the Companies Act 61 of 1973 does not invariably constitute a 'debt' as defined in the Prescription Act 68 of 1969. The term 'debt' must be given a narrow meaning consistent with Makate v Vodacom and Escom: that which is owed or due; anything (as money, goods or services) which one person is under obligation to pay or render to another. A section 252 claim is an entitlement to seek an equitable judicial determination regarding whether conduct is unfairly prejudicial, unjust or inequitable, with the court having wide discretion to grant just and equitable relief. This does not constitute an obligation to pay money, deliver goods or render services. The correct characterization of a claim for prescription purposes arises from the relevant legal provisions on which the claim is based, not the ultimate effects or aims of the relief sought. Section 252(3) provides an internal equitable mechanism for courts to consider delay and what may have prescribed when determining just and equitable relief, such that the Prescription Act need not bar such claims entirely. Prescribed debts forming part of the history of a company's conduct can be considered in granting contemporaneous just and equitable relief regarding corporate governance, without reviving those prescribed debts.

Mhlantla J observed that section 252 encompasses the concept of fairness as an objective criterion by which courts must decide whether they have jurisdiction to grant relief. The section confers wide and unfettered discretion to do what is fair and equitable to cure unfair prejudice suffered by members at the hands of a company. The section is about institutional governance and provides a crucial mechanism to keep corporate bullying at bay. It must be given a construction that advances the remedy rather than limits it. Froneman J observed that there is a need for a more open debate about the substantive reasons for excluding certain claims from the definition of 'debt,' including claims based on fundamental rights or historical injustice. He noted that fairness as a legal requirement should not be rigidly distinguished from law, which is increasingly recognized as discordant with constitutional values. He cautioned that the existence of a discretionary remedy does not itself exclude the Prescription Act, noting that section 172(1) of the Constitution provides wide remedial powers yet has not precluded recognition of prescription. Madlanga J observed that focusing on the remedy rather than the underlying conduct risks allowing ingenious litigants to circumvent prescription through strategic framing of claims. This approach could defeat the primary objectives of prescription: bringing certainty and stability to legal affairs and maintaining the quality of adjudication. He noted that prescription may not be raised by a court of its own accord, so respondents must be able to identify prescribable claims objectively.

This case is significant in South African law because it clarifies the scope of claims that fall within the definition of 'debt' under the Prescription Act following Makate v Vodacom. It establishes that statutory claims for equitable relief under section 252 of the Companies Act do not invariably constitute 'debts' capable of prescription. The judgment protects the remedial nature of section 252, which provides an important tool for minority shareholders to obtain relief from oppressive conduct. It affirms that equitable statutory remedies with wide judicial discretion to grant 'just and equitable' relief fall outside the ordinary ambit of prescription. The decision demonstrates the Constitutional Court's interpretation of prescription legislation in light of the constitutional right of access to courts (section 34). It also addresses the interaction between statutory remedies and common law prescription principles. The case has important implications for corporate governance, minority shareholder protection, and the temporal limits on seeking equitable relief. The multiple judgments reflect ongoing judicial debate about the proper approach to defining 'debt' and the scope of prescription in South African law.